Literature DB >> 19580833

Changes in activatory and inhibitory natural killer (NK) receptors may induce progression to multiple myeloma: implications for tumor evasion of T and NK cells.

Mónica Bernal1, Pilar Garrido, Pilar Jiménez, Rafael Carretero, Manuel Almagro, Pilar López, Pilar Navarro, Federico Garrido, Francisco Ruiz-Cabello.   

Abstract

The molecular basis of monoclonal gammopathy of undetermined significance (MGUS) progression to a malignant monoclonal gammopathy remains poorly understood. It was recently suggested that this process involves the suppression of innate and adaptive immunity. In this study, we examined immunogenic differences in bone marrow plasma cells among individuals without gammopathy (controls) and patients with MGUS, multiple myeloma (MM), and plasma cell leukemia. We detected differences in major histocompatibility complex (MHC) class I expression, MHC class I chain-related molecule A, and CD95 that were more evident between MGUS and MM samples; there appeared to be a critical imbalance between natural killer (NK)-cell activating and inhibitory signals during the transition from MGUS to MM. Our results indicate that the human leukocyte antigen (HLA) class I(bright), MICA(dim/-), and CD95(dim/-) immunophenotype reported in myeloma cells may result from an extensive interaction of malignant cells with cytotoxic T and NK cells and appears to be immunoedited for the evasion of immunosurveillance.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19580833     DOI: 10.1016/j.humimm.2009.07.004

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  23 in total

1.  Transcriptional heterogeneity of clonal plasma cells and immune evasion in immunoglobulin light chain amyloidosis.

Authors:  Yujia Wang; Lushuang Xu; Yang Liu; Yuzhe Hu; Qiang Shi; Lixue Jin; Lijun Yang; Pingzhang Wang; Kunshan Zhang; Xiaojun Huang; Qing Ge; Jin Lu
Journal:  Int J Hematol       Date:  2020-10-10       Impact factor: 2.490

Review 2.  Lenalidomide: a review of its use in the treatment of relapsed or refractory multiple myeloma.

Authors:  Lesley J Scott; Katherine A Lyseng-Williamson
Journal:  Drugs       Date:  2011-03-26       Impact factor: 9.546

Review 3.  Myelomagenesis: capturing early microenvironment changes.

Authors:  Neha Korde; Irina Maric
Journal:  Semin Hematol       Date:  2011-01       Impact factor: 3.851

Review 4.  Checkpoint inhibition in myeloma.

Authors:  Don M Benson
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

Review 5.  Utilizing cell-based therapeutics to overcome immune evasion in hematologic malignancies.

Authors:  Chuang Sun; Gianpietro Dotti; Barbara Savoldo
Journal:  Blood       Date:  2016-05-20       Impact factor: 22.113

6.  Overexpression of KIR inhibitory ligands (HLA-I) determines that immunosurveillance of myeloma depends on diverse and strong NK cell licensing.

Authors:  María V Martínez-Sánchez; Adela Periago; Isabel Legaz; Lourdes Gimeno; Anna Mrowiec; Natividad R Montes-Barqueros; José A Campillo; José M Bolarin; María V Bernardo; María R López-Álvarez; Consuelo González; María C García-Garay; Manuel Muro; Valentin Cabañas-Perianes; Jose L Fuster; Ana M García-Alonso; José M Moraleda; María R Álvarez-Lopez; Alfredo Minguela
Journal:  Oncoimmunology       Date:  2015-10-29       Impact factor: 8.110

Review 7.  Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies.

Authors:  Camille Guillerey; Kyohei Nakamura; Slavica Vuckovic; Geoffrey R Hill; Mark J Smyth
Journal:  Cell Mol Life Sci       Date:  2016-01-22       Impact factor: 9.261

Review 8.  The Role of Marrow Microenvironment in the Growth and Development of Malignant Plasma Cells in Multiple Myeloma.

Authors:  Nikolaos Giannakoulas; Ioannis Ntanasis-Stathopoulos; Evangelos Terpos
Journal:  Int J Mol Sci       Date:  2021-04-24       Impact factor: 5.923

9.  Optimal selection of natural killer cells to kill myeloma: the role of HLA-E and NKG2A.

Authors:  Subhashis Sarkar; Michel van Gelder; Willy Noort; Yunping Xu; Kasper M A Rouschop; Richard Groen; Harry C Schouten; Marcel G J Tilanus; Wilfred T V Germeraad; Anton C M Martens; Gerard M J Bos; Lotte Wieten
Journal:  Cancer Immunol Immunother       Date:  2015-04-29       Impact factor: 6.968

10.  Development of [89Zr]DFO-elotuzumab for immunoPET imaging of CS1 in multiple myeloma.

Authors:  Anchal Ghai; Alexander Zheleznyak; Matt Mixdorf; Julie O'Neal; Julie Ritchey; Michael Rettig; John DiPersio; Monica Shokeen; Samuel Achilefu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-11-11       Impact factor: 10.057

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.